The emergence of Data Security Posture Management (DSPM) in early 2023, followed by major acquisitions by companies like IBM, Thales, and Palo Alto Networks, demonstrates industry recognition of the need for a more holistic approach to data protection.
Malicious NPM Packages Disguised With ‘Invisible’ Dependencies
In the “PhantomRaven” campaign, threat actors published 126 malicious npm packages that have flown under the radar, while collecting 86,000 downloads.
AI Search Tools Easily Fooled by Fake Content
New research shows AI crawlers like Perplexity, Atlas, and ChatGPT are surprisingly easy to fool.
Dentsu Subsidiary Breached, Employee Data Stolen
A subsidiary of Japanese marketing and PR giant Dentsu lost sensitive data to unidentified threat actors, the parent company said.
BIO chief to senators: China could pass US within two years
The US is at risk of losing its global lead in biotech. That was the warning Wednesday from John Crowley, CEO of the Biotechnology Innovation Organization — better known as BIO — during a sprawling Senate HELP …
Thermo Fisher to buy data solutions-focused Clario for up to $9.4B
Thermo Fisher announced Wednesday that it will pay $8.9 billion in cash to acquire the data solutions company Clario. In addition to the upfront payment, Thermo has agreed to shell out $125 million in January …
GSK confirms it has completed IRA negotiations ahead of CMS deadline
GSK’s incoming CEO Luke Miels said Wednesday that Medicare negotiations for the company’s top-selling respiratory product Trelegy Ellipta have concluded “in line with expectations.” The company is one of the first to disclose that it …
Microsoft Security Change for Azure VMs Creates Pitfalls
Firms using Azure infrastructure gained a reprieve from a security-focused switch that could have broken apps that relied on public Internet access.
Lilly budgets $1.2B for GLP-1 pill factory in Puerto Rico
Eli Lilly is making another move to help boost production for its oral GLP-1 franchise, with a new $1.2 billion factory in Puerto Rico. Construction for the facility dedicated to make orforglipron will
Ventus stops Phase 2 of NLRP3 inhibitor that was being tested in Parkinson’s
Ventus Therapeutics has terminated a Phase 2a trial of an NLRP3 inhibitor, an en vogue class with broad potential in neurology, obesity and other areas. The drug, VENT-02, was being tested …